How did you decide where to focus limited resources? And how did you prioritize what to build first versus what to wait?

Yeah, it's a really important question because as a nonprofit, resources are always limited.

And what we did is we looked at the landscape holistically together with our SAP, our Scientific Advisory Board.

And then we thought backwards from the final goal of getting into clinical trials.

And we asked, you know, what's missing? What would make the biggest impact? And so one of the things we did early on was create patient cell lines that can, these so-called iPSC cell lines that can be grown into neurons in a dish and other cells of interest.

And lines were out there and there was a characterized model for cleavage neurons grown in dishes.

And so they have a known phenotype, but those lines were siloed.

Are there other therapeutic approaches that iDefine's exploring or considers promising for cleavage syndrome?